Kinderhook Industries has completed its acquisition of Enhabit, taking the home health and hospice provider private at $13.80 a share in cash and ending its New York Stock Exchange listing. The deal closes a difficult chapter for Enhabit as a public company and opens a more familiar one for healthcare services investors who prefer to fix reimbursement, labor, and margin issues away from quarterly scrutiny.
Enhabit brings real scale. The company operates 251 home health locations and 117 hospice sites across 35 states, giving Kinderhook a national platform in one of the few healthcare segments still benefiting from a structural shift out of higher-cost settings. That footprint matters. Home-based care remains fragmented, local, and operationally demanding. Buyers are not just purchasing revenue. They are buying referral relationships, clinician density, and the ability to spread compliance and technology costs across a wider network.
For Kinderhook, this looks less like a simple take-private and more like a platform investment built for follow-on acquisitions. Private equity has long favored home health and hospice because scale can improve payer contracting, back-office efficiency, and recruiting economics. The harder question is whether scale alone can offset persistent pressure from wage inflation and government reimbursement resets. Taking Enhabit private gives management more room to restructure branch performance, sharpen market selection, and pursue tuck-ins without the public market discount attached to uneven earnings.
The timing also fits a market that is rewarding larger healthcare bets. Acquire.fyi data shows health sector deal value has reached $75.3 billion year to date, up 88.2% from a year earlier, while median deal size has climbed to $3.5 billion. That points to a buyer preference for scaled assets with room for operational improvement rather than smaller speculative plays.
Expect rivals and sponsors to keep hunting in adjacent home-based care categories, especially assets that can connect post-acute services with hospice and palliative care. Regulators are unlikely to challenge this transaction on concentration grounds, but reimbursement policy will remain the real gatekeeper. In home care, Washington often has more influence on returns than Wall Street.
Source: Company press release and Acquire.fyi's proprietary data
